Clearing away neurodegenerative disease

PRECISION MEDICINE TO PRESERVE NEURONS

Caraway Therapeutics is an emerging biopharmaceutical company pursuing novel approaches for the treatment of debilitating neurodegenerative diseases by preserving neurons. It is a leader in the cutting-edge science of activating cellular recycling processes to clear toxic materials and defective cellular components (autophagy), an exciting new focus for potential therapeutics. Caraway has a rigorous, scientific product engine with multiple approaches, using genetically defined targets to find potential treatments related to these processes.

Urgent, Unmet Medical Need

Targeted Approach

Leveraging Advances in Neuroscience

Neurodegenerative diseases represent an urgent and expanding unmet medical need. Caraway’s approach to developing targeted treatments leverages the body’s natural ability to identify toxic cellular materials and enhances their clearance, preventing loss of neurons. By increasing lysosomal flux, Caraway’s small molecules can stimulate clearance of dysfunctional cellular components.

News

January 25, 2021

Caraway Therapeutics to Present at the Oppenheimer Winter Private Company Showcase

November 18, 2020

Caraway Therapeutics Receives Research Grant from The Michael J. Fox Foundation to Further Investigate the Function of the Lysosomal Ion Channel TMEM175 and Gene Variants Linked to Parkinson’s Disease

Our Team

Solutions to complex problems require an unique combination of rigor and creativity. The Caraway team drives our development programs forward by bringing passion and precision to our work every day.